Amanda Heslegrave, PhD, University College London, London, UK, shares insights on promising diagnostic biomarkers under development for use in Alzheimer’s disease (AD) clinical practice. In recent years, there has been substantial growth in the use of fluid biomarkers in research settings, to optimize trial enrolment, measure target engagement, act as surrogates for clinical outcomes, and enhance our understanding of disease pathophysiology and drug action. A major next goal is to develop assays that can be used for diagnosis in every practice. Validation of p-tau in the blood is a key focus of many research groups currently. Reproducibility, reliability, sensitivity and specificity must all be demonstrated, as well as the determining the feasibility of real-world application and the impact of certain methodological and biological factors. Dr Heslegrave comments on the putative benefits of such a biomarker. This interview took place at the Alzheimer’s Research UK (ARUK) Conference 2023 in Aberdeen, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
